OncoSynergy Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Private

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $6.16M

  • Investors
  • 17

OncoSynergy General Information

Description

Developer of novel immunotherapies designed to improve outcomes for cancer patients. The company's immunotherapies employ a transformative strategy based on the resistance mechanism inhibitors principle that inhibits several cancer-driving pathways simultaneously, enabling oncologists to provide durable outcomes and cures for patients.

Contact Information

Website
www.oncosynergy.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 850 Pacific Street
  • Unit 1802
  • Stamford, CT 06902
  • United States
+1 (415)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 850 Pacific Street
  • Unit 1802
  • Stamford, CT 06902
  • United States
+1 (415)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

OncoSynergy Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Later Stage VC 13-May-2022 $6.16M Completed Clinical Trials - Phase 1
9. Later Stage VC 08-Sep-2020 Completed Clinical Trials - Phase 1
8. Grant 20-Sep-2019 Completed Clinical Trials - General
7. Grant 01-Jan-2019 Completed Clinical Trials - General
6. Later Stage VC (Series A) 14-May-2018 Completed Clinical Trials - General
5. Accelerator/Incubator 19-May-2017 Completed Clinical Trials - General
4. Accelerator/Incubator Completed Clinical Trials - General
3. Merger/Acquisition 05-Apr-2016 Cancelled Clinical Trials - General
2. Equity Crowdfunding 28-Jun-2015 $178K $178K Completed Clinical Trials - General
1. University Spin-Out 01-Jan-2011 Completed Startup
To view OncoSynergy’s complete valuation and funding history, request access »

OncoSynergy Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A1
Series A
To view OncoSynergy’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

OncoSynergy Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of novel immunotherapies designed to improve outcomes for cancer patients. The company's immunotherapies emplo
Drug Discovery
Stamford, CT
6 As of 2025

New York, NY

Gaithersburg, MD
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

OncoSynergy Competitors (44)

One of OncoSynergy’s 44 competitors is Innovimmune Biotherapeutics, a Accelerator/Incubator Backed company based in New York, NY.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Innovimmune Biotherapeutics Accelerator/Incubator Backed New York, NY
NexImmune Formerly VC-backed Gaithersburg, MD
Meditope Biosciences Venture Capital-Backed Pasadena, CA
CytomX Therapeutics Formerly VC-backed South San Francisco, CA
Centrose Venture Capital-Backed Madison, WI
You’re viewing 5 of 44 competitors. Get the full list »

OncoSynergy Patents

  • 40

    Total Documents Applications and Grants

  • Total Patents Families

  • 29

    Granted

  • 1

    Pending

  • Expiring in next 12 mo

OncoSynergy Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2013370467-A1 Anti- integrin beta1 antibody compositions and methods of use thereof Active 26-Dec-2012
AU-2013370467-B2 Anti- integrin beta1 antibody compositions and methods of use thereof Active 26-Dec-2012
AU-2018260887-A1 Anti- integrin beta1 antibody compositions and methods of use thereof Inactive 26-Dec-2012
EP-2938359-A1 Anti- integrin beta1 antibody compositions and methods of use thereof Inactive 26-Dec-2012
EP-2938359-A4 Anti- integrin beta1 antibody compositions and methods of use thereof Inactive 26-Dec-2012 C07K16/2842
To view OncoSynergy’s complete patent history, request access »

OncoSynergy Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

OncoSynergy Investors (17)

Investor Name Investor Type Holding Investor Since Participating Rounds
National Cancer Institute Government
National Institutes of Neurological Disorders and Stroke Government
Connecticut Innovations Venture Capital Minority
Korea Information & Communications Corporation Minority
NLabs Family Office Minority
You’re viewing 5 of 17 investors. Get the full list »

OncoSynergy Acquisitions (1)

OncoSynergy’s most recent deal was a Merger/Acquisition with NexGenix Pharmaceuticals. The deal was made on 01-May-2013.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
NexGenix Pharmaceuticals 01-May-2013 Merger/Acquisition Pharmaceuticals
To view OncoSynergy’s complete acquisitions history, request access »

Ready to get started?

Request a free trial

OncoSynergy FAQs

  • When was OncoSynergy founded?

    OncoSynergy was founded in 2011.

  • Where is OncoSynergy headquartered?

    OncoSynergy is headquartered in Stamford, CT.

  • What is the size of OncoSynergy?

    OncoSynergy has 6 total employees.

  • What industry is OncoSynergy in?

    OncoSynergy’s primary industry is Drug Discovery.

  • Is OncoSynergy a private or public company?

    OncoSynergy is a Private company.

  • What is OncoSynergy’s current revenue?

    The current revenue for OncoSynergy is .

  • How much funding has OncoSynergy raised over time?

    OncoSynergy has raised $29.6M.

  • Who are OncoSynergy’s investors?

    National Cancer Institute, National Institutes of Neurological Disorders and Stroke, Connecticut Innovations, Korea Information & Communications, and NLabs are 5 of 17 investors who have invested in OncoSynergy.

  • Who are OncoSynergy’s competitors?

    Innovimmune Biotherapeutics, NexImmune, Meditope Biosciences, CytomX Therapeutics, and Centrose are some of the 44 competitors of OncoSynergy.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »